Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization

Nature Structural and Molecular Biology

Volumn 18, Issue 11, 2011, Pages 1235-1243

  Kim, Mikyung ^a   Sun, Zhen Yu J ^a   Rand, Kasper D ^b   Shi, Xiaomeng ^b   Song, Likai ^a,c   Cheng, Yuxing ^a,d   Fahmy, Amr F ^a   Majumdar, Shreoshi ^a   Ofek, Gilad ^e   Yang, Yongping ^e   Kwong, Peter D ^e   Wang, Jia Huai ^a   Engen, John R ^b   Wagner, Gerhard ^a   Reinherz, Ellis L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c FLORIDA STATE UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE H2A; HISTONE H4; POLYCOMB GROUP PROTEIN; PROTEIN NUA4; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOCHEMISTRY; CATALYSIS; CELL INTERACTION; CONTROLLED STUDY; EUKARYOTIC CELL; HISTONE ACETYLATION; HUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN MICROARRAY; PROTEIN STRUCTURE; YEAST;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; BINDING SITES; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MEMBRANE LIPIDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80555131011     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2154     Document Type: Article

References (59)

1. McElrath, M.J. & Haynes, B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33, 542-554 (2010).
2. Han, Y., Wind-Rotolo, M., Yang, H.C., Siliciano, J.D. & Siliciano, R.F. Experimental approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 5, 95-106 (2007). (Pubitemid 46151868)
3. Feng, Y., Broder, C.C., Kennedy, P.E. & Berger, E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877 (1996). (Pubitemid 26154590)
4. Chan, D.C., Fass, D., Berger, J.M. & Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997). (Pubitemid 27199898)
5. Harrison, S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690-698 (2008). (Pubitemid 351932011)
6. Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144-4149 (2003). (Pubitemid 36418171)
7. Kwong, P.D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002). (Pubitemid 36764500)
8. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003). (Pubitemid 36378357)
9. Simek, M.D. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337-7348 (2009).
10. Cardoso, R.M. et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22, 163-173 (2005). (Pubitemid 40255708)
11. Muster, T. et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68, 4031-4034 (1994). (Pubitemid 24177431)
12. Nelson, J.D. et al. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81, 4033-4043 (2007). (Pubitemid 46586898)
13. Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108 (1996). (Pubitemid 26029030)
14. Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
15. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
16. Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732-737 (2007). (Pubitemid 46279718)
17. Salzwedel, K., West, J.T. & Hunter, E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73, 2469-2480 (1999). (Pubitemid 29098154)
18. Sun, Z.Y. et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28, 52-63 (2008).
19. Ofek, G. et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737 (2004). (Pubitemid 39258398)
20. Julien, J.P., Bryson, S., Nieva, J.L. & Pai, E.F. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J. Mol. Biol. 384, 377-392 (2008).
21. Alam, S.M. et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178, 4424-4435 (2007). (Pubitemid 46492394)
22. Sánchez-Martínez, S. et al. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett. 580, 2395-2399 (2006). (Pubitemid 43675634)
23. Scherer, E.M., Leaman, D.P., Zwick, M.B., McMichael, A.J. & Burton, D.R. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc. Natl. Acad. Sci. USA 107, 1529-1534 (2010).
24. Julien, J.P. et al. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J. Virol. 84, 4136-4147 (2010).
25. Xu, H. et al. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J. Virol. 84, 1076-1088 (2010).
26. Ofek, G. et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J. Virol. 84, 2955-2962 (2010).
27. Zwick, M.B. et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J. Virol. 78, 3155-3161 (2004). (Pubitemid 38314375)
28. Alam, S.M. et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 106, 20234-20239 (2009).
29. Guenaga, J. et al. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 6, e16074 (2011).
30. Ofek, G. et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. USA 107, 17880-17887 (2010).
31. Wales, T.E. & Engen, J.R. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom. Rev. 25, 158-170 (2006).
32. Wales, T.E., Fadgen, K.E., Gerhardt, G.C. & Engen, J.R. High-speed and high-resolution UPLC separation at zero degrees celsius. Anal. Chem. 80, 6815-6820 (2008).
33. Miranker, A., Robinson, C.V., Radford, S.E., Aplin, R.T. & Dobson, C.M. Detection of transient protein folding populations by mass spectrometry. Science 262, 896-900 (1993). (Pubitemid 24014076)
34. Weis, D.D., Wales, T.E., Engen, J.R., Hotchko, M. & Ten Eyck, L.F. Identification and characterization of EX1 kinetics in H/D exchange mass spectrometry by peak width analysis. J. Am. Soc. Mass Spectrom. 17, 1498-1509 (2006). (Pubitemid 44635272)
35. Song, L. et al. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc. Natl. Acad. Sci. USA 106, 9057-9062 (2009).
36. Takahashi, H., Nakanishi, T., Kami, K., Arata, Y. & Shimada, I. A novel NMR method for determining the interfaces of large protein-protein complexes. Nat. Struct. Biol. 7, 220-223 (2000). (Pubitemid 30140768)
37. Bryson, S., Julien, J.P., Hynes, R.C. & Pai, E.F. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J. Virol. 83, 11862-11875 (2009).
38. Tian, Y. et al. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints. J. Pept. Res. 59, 264-276 (2002). (Pubitemid 34539065)
39. Huang, C.C. et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317, 1930-1934 (2007).
40. Andreotti, A.H. Native state proline isomerization: an intrinsic molecular switch. Biochemistry 42, 9515-9524 (2003). (Pubitemid 36993127)
41. Lummis, S.C.R. et al. Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. Nature 438, 248-252 (2005). (Pubitemid 41599879)
42. Padlan, E.A. Anatomy of the antibody molecule. Mol. Immunol. 31, 169-217 (1994). (Pubitemid 24071681)
43. Klein, J.S. et al. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl. Acad. Sci. USA 106, 7385-7390 (2009).
44. Collis, A.V., Brouwer, A.P. & Martin, A.C. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J. Mol. Biol. 325, 337-354 (2003). (Pubitemid 36062692)
45. Johnson, G. & Wu, T.T. Preferred CDRH3 lengths for antibodies with defined specificities. Int. Immunol. 10, 1801-1805 (1998). (Pubitemid 28566041)
46. Kunert, R., Ruker, F. & Katinger, H. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res. Hum. Retroviruses 14, 1115-1128 (1998). (Pubitemid 28409164)
47. Xiao, X. et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390, 404-409 (2009).
48. Xiao, X., Chen, W., Feng, Y. & Dimitrov, D.S. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 1, 802-817 (2009).
49. Yin, J., Beuscher, A.E.t., Andryski, S.E., Stevens, R.C. & Schultz, P.G. Structural plasticity and the evolution of antibody affinity and specificity. J. Mol. Biol. 330, 651-656 (2003).
50. Mikell, I. et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7, e1001251 (2011).
51. Kim, S.T. et al. The αβ T cell receptor is an anisotropic mechanosensor. J. Biol. Chem. 284, 31028-31037 (2009).
52. Schmitz, K.R. & Ferguson, K.M. Interaction of antibodies with ErbB receptor extracellular regions. Exp. Cell Res. 315, 659-670 (2009).
53. Janssen, B.J. et al. Structural basis of semaphorin-plexin signalling. Nature 467, 1118-1122 (2010).
54. Pejchal, R. et al. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J. Virol. 83, 8451-8462 (2009).
55. Wales, T.E., Fadgen, K.E., Gerhardt, G.C. & Engen, J.R. High-speed and high-resolution UPLC separation at zero degrees Celsius. Anal. Chem. 80, 6815-6820 (2008).
56. Wang, L., Pan, H. & Smith, D.L. Hydrogen exchange-mass spectrometry: optimization of digestion conditions. Mol. Cell. Proteomics 1, 132-138 (2002).
57. Weis, D.D., Engen, J.R. & Kass, I.J. Semi-automated data processing of hydrogen exchange mass spectra using HX-Express. J. Am. Soc. Mass Spectrom. 17, 1700-1703 (2006). (Pubitemid 44809951)
58. Houde, D., Berkowitz, S.A. & Engen, J.R. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J. Pharm. Sci. 100, 2071-2086 (2011).
59. Shimada, I. NMR techniques for identifying the interface of a larger protein-protein complex: cross-saturation and transferred cross-saturation experiments. Methods Enzymol. 394, 483-506 (2005). (Pubitemid 40460929)